IBRX
ImmunityBio, Inc. · Healthcare · Biotechnology
$10.28
+10.83% today · +21.86% 1W
Oct 2 close or latest
PreviewWhy it's moving
Outperforming without a clear catalyst yet
- IBRX +10.83% on the last session vs SPY +0.74%: +10.1 pts of stock-specific move.
- Aftermath, rsi overbought (Oct 2): After its 11 overbought readings in the past 5 years, IBRX typically lost 5.3% over the next month (median) and was higher only 45% of the time; half the outcomes fell between -16.9% and +32.6%. An ordinary month: -1.8%. Among S&P 500 stocks after overbought readings, that ranks #263 of 501.
- 0 Reddit mentions in the past 24 hours, 81% positive over the week · today's pace is 1.5× its recent daily average.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Key facts
- Market cap
- $10.9B
- Held by institutions
- 19.8%
- Short interest
- 31.3%
- 52-week range
- 1.95–12.43
- Analyst mean target
- $13.00
- Next earnings
- Nov 3 est.
- Forward P/E
- -73.5
Recent events
Earnings ▼
2Q2026 results: EPS −$0.22 vs −$0.08 expected miss −$0.14; next session -2.8% (-4.6 vs SPY)Insider ▼
Cheryl Cohen (Director) sold 131,210 shares ($1.2M) under a pre-arranged 10b5-1 plan 10b5-1 plan · filingInsider ▼
Christobel Selecky (Director) sold 159,478 shares ($1.4M) under a pre-arranged 10b5-1 plan 10b5-1 plan · filingInsider ▼
Christobel Selecky (Director) sold 96,722 shares ($871.2K) under a pre-arranged 10b5-1 plan 10b5-1 plan · filingInsider ▼
Barry J. Simon (Director) sold 25,000 shares ($196.9K) under a pre-arranged 10b5-1 plan 10b5-1 plan · filingInsider ▼
Barry J. Simon (Director) sold 23,033 shares ($165.3K) under a pre-arranged 10b5-1 plan 10b5-1 plan · filingAnalyst
HC Wainwright & Co. reiterated Buy, target $15.00Analyst
BTIG reiterated Buy, target $12.00Analyst
HC Wainwright & Co. reiterated Buy, target $15.00Earnings ▼
1Q2026 results: EPS −$0.08 vs −$0.07 expected miss −$0.01; revenue $44.2M; next session -7.4% (-7.1 vs SPY)